Warfarin product now substitutable due to scarcity

empty box
Coumadin 5mg tablets is the subject of a new Serious Scarcity Substitution Instrument In early March, the Therapeutic Goods Administration issued an advisory that several warfarin products were in shortage, due to manufacturing issues, including Coumadin (warfarin sodium) 2mg and 5mg tablets. While supply of some strengths has improved since, the TGA now says that

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Choosing a banner group: the market perspective
Next Blooms secures B Corp certification